DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for autosomal dominant osteopetrosis 2 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAutosomal dominant osteopetrosis 2 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for autosomal dominant osteopetrosis 2 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
The 1987 review of radiographs from 26 patients with autosomal dominant osteopetrosis identified two distinct family-related radiographic types. Type 1 showed pronounced sclerosis of the cranial vault with the spine almost unaffected. Type 2 had sclerosis most pronounced at the skull base, vertebrae with end-plate thickening, and convex arcs of sclerotic bone in the iliac wings. Age and sex distribution did not differ between the two types. The authors concluded that autosomal dominant osteopetrosis may be a heterogeneous group of inherited bone disorders.
A 2013 case report described a 35-year-old woman with autosomal dominant osteopetrosis type II who had chronic generalised periodontitis. Radiographs showed generalised osteosclerosis, a "bone-within-bone appearance," and "Erlenmeyer-flask deformity." A 2009 case report and a 2016 case report each described an asymptomatic 14-year-old (a girl and a boy, respectively) with the benign autosomal dominant form. No drug treatment was mentioned in any of these reports.
A 2022 review focused on the autosomal recessive form caused by OSTM1 mutations, which accounts for about 5% of autosomal recessive osteopetrosis cases. That form leads to severe disease in infancy and death within the first few years of life. The review noted that OSTM1 plays a direct role in the central nervous system and that its trafficking function is essential for osteoclast maturation. This is a different, more severe disease than the autosomal dominant type 2.
No clinical trial data, no drug intervention, and no measured survival or response rates exist in these abstracts for autosomal dominant osteopetrosis type 2. What is missing is any trial design, any patient stratification beyond radiographic typing, and any funding for a drug-repurposing study in this specific subtype.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Radiology · 1987 · 92 citations
Heterogeneity of autosomal dominant osteopetrosis.
AbstractA review of the radiographs of 26 patients with autosomal dominant osteopetrosis disclosed two distinct and strictly family-related radiographic types. Both types had universal osteosclerosis. In type 1 the most striking finding was pronounced sclerosis of the cranial vault while the spine was almost unaffected. In type 2 the sclerosis of the skull was most pronounced at the base, the vertebrae always had end-plate thickening, and in the pelvis the iliac wings contained convex arcs of sclerotic bone. Age and sex distribution did not differ between the types. Autosomal dominant osteopetrosis may be a heterogeneous group of inherited bone disorders.
Case Reports in Dentistry · 2013 · 17 citations · open access
Clinical and Radiological Findings of Autosomal Dominant Osteopetrosis Type II: A Case Report
AbstractOsteopetrosis is a rare inherited genetic disease characterized by sclerosis of the skeleton caused by the absence or malfunction of osteoclasts. Three distinct forms of the disease have been recognized, autosomal dominant osteopetrosis being the most common. Autosomal dominant osteopetrosis exhibits a heterogeneous trait with milder symptoms, often at later childhood or adulthood. The aim of this case report is to present the clinical and radiographic features of a 35-year-old female patient with autosomal dominant osteopetrosis type II who exhibited features of chronic generalised periodontitis, and the radiographs revealed generalised osteosclerosis and hallmark radiographic features of ADO type II, that is, "bone-within-bone appearance" and "Erlenmeyer-flask deformity."
OSTM1 pleiotropic roles from osteopetrosis to neurodegeneration
AbstractAutosomal recessive osteopetroses (ARO) are rare genetic skeletal disorders of high clinical and molecular heterogeneity with an estimated frequency of 1:250,000 worldwide. The manifestations are diverse and although individually rare, the various forms contribute to the prevalence of a significant number of affected individuals with considerable morbidity and mortality. Among the ARO classification, the most severe form is the autosomal recessive-5 (OPTB5) osteopetrosis (OMIM 259720 ) that results from homozygous mutation in the OSTM1 gene (607649). OSTM1 mutations account for approximately 5 % of instances of autosomal recessive osteopetrosis and lead to a highly debilitating form of the disease in infancy and death within the first few years of life (Sobacchi et al., 2013) [1] . • OSTM1 is the more severe form of ARO in mice and humans. • The OSTM1 protein trafficking function is essential for osteoclast maturation. • OSTM1 plays a primary and direct role in the central nervous system.
International Journal of Medical and Dental Case Reports · 2016 · 6 citations
Osteopetrosis: A case report
AbstractOsteopetrosis is an uncommon skeletal disorder characterized by generalized sclerosis of bones due to defective osteoclast function. A wide variation in clinical severity of the disease may be noted. Radiographic features are usually diagnostic. A case of benign autosomal dominant form of osteopetrosis in an asymptomatic 14-year-old boy is hereby reported.
TAJ Journal of Teachers Association · 2009 · 0 citations · open access
Autosomal Dominant Type II Osteopctrosis in an Asymptomatic Adolescent: A Case Report
AbstractOsteopetrosis is a heterogeneous group of heritable conditions in which there is a defect in bone resorption by osteoclasts. The disease has variable mode of inheritance with variable expression of severity. We are reporting a 14 year old asymptomatic girl with autosomal dominant type II osteopetrosis and then the literature is reviewed.TAJ 2009; 22(1): 251-254
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
